Literature DB >> 35258675

MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification.

Ja Kyung Yoon1, Jin-Young Choi2, Hyungjin Rhee1, Young Nyun Park3.   

Abstract

HCC is a heterogeneous group of tumors in terms of histology, genetic aberration, and protein expression. Advancements in imaging techniques have allowed imaging diagnosis to become a critical part of managing HCC in the clinical setting, even without pathologic diagnosis. With the identification of many HCC subtypes, there is increasing correlative evidence between imaging phenotypes and histologic, molecular, and genetic characteristics of various HCC subtypes. In this review, current knowledge of histologic heterogeneity of HCC correlated to features on gadolinium-enhanced dynamic liver MRI will be discussed. In addition, HCC subtype classification according to transcriptomic profiles will be outlined with descriptions of histologic, genetic, and molecular characteristics of some relatively well-established morphologic subtypes, namely the low proliferation class (steatohepatitic HCC and CTNNB1-mutated HCC) and the high proliferation class (macrotrabecular-massive HCC (MTM-HCC), scirrhous HCC, and CK19-positive HCC). Characteristics of sarcomatoid HCC and fibrolamellar HCC will also be discussed. Further research on radiological characteristics of HCC subtypes may ultimately enable non-invasive diagnosis and serve as a biomarker in predicting prognosis, molecular characteristics, and therapeutic response. In the era of precision medicine, a multidisciplinary effort to develop an integrated radiologic and clinical diagnostic system of various HCC subtypes is necessary. KEY POINTS: • HCC is a heterogeneous group of tumors in terms of histology, genetic aberration, and protein expression, which can be divided into many subtypes according to transcriptome profiles. • There is increasing evidence of a correlation between imaging phenotypes and histologic, genetic, and molecular biologic characteristics of various HCC subtypes. • Imaging characteristics may ultimately enable non-invasive diagnosis and subtype characterization, serving as a biomarker for predicting prognosis, molecular characteristics, and therapeutic response.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Carcinoma, hepatocellular; Histology; Magnetic resonance imaging; Radiology; Transcriptome

Mesh:

Substances:

Year:  2022        PMID: 35258675     DOI: 10.1007/s00330-022-08643-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  94 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

2.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

Review 4.  Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Authors:  Norihide Yoneda; Osamu Matsui; Satoshi Kobayashi; Azusa Kitao; Kazuto Kozaka; Dai Inoue; Kotaro Yoshida; Tetsuya Minami; Wataru Koda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2019-02-02       Impact factor: 2.374

Review 5.  Molecular and histological correlations in liver cancer.

Authors:  Julien Calderaro; Marianne Ziol; Valérie Paradis; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2019-06-10       Impact factor: 25.083

6.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Authors:  Julien Calderaro; Gabrielle Couchy; Sandrine Imbeaud; Giuliana Amaddeo; Eric Letouzé; Jean-Frédéric Blanc; Christophe Laurent; Yacine Hajji; Daniel Azoulay; Paulette Bioulac-Sage; Jean-Charles Nault; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2017-05-19       Impact factor: 25.083

Review 7.  Hepatocarcinogenesis: imaging-pathologic correlation.

Authors:  Young Nyun Park; Myeong-Jin Kim
Journal:  Abdom Imaging       Date:  2011-06

Review 8.  Epidemiology and natural history of hepatocellular carcinoma.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-02       Impact factor: 3.043

Review 9.  Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC.

Authors:  R Stigliano; L Marelli; D Yu; N Davies; D Patch; A K Burroughs
Journal:  Cancer Treat Rev       Date:  2007-05-18       Impact factor: 12.111

10.  Primary Liver Cancers-Part 1: Histopathology, Differential Diagnoses, and Risk Stratification.

Authors:  Kun Jiang; Sameer Al-Diffhala; Barbara A Centeno
Journal:  Cancer Control       Date:  2018 Jan-Mar       Impact factor: 3.302

View more
  2 in total

1.  A preoperative model based on gadobenate-enhanced MRI for predicting microvascular invasion in hepatocellular carcinomas (≤ 5 cm).

Authors:  Sisi Zhang; Lei Huo; Juan Zhang; Yayuan Feng; Yiping Liu; Yuxian Wu; Ningyang Jia; Wanmin Liu
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

Review 2.  A Multidisciplinary Approach to the Management of Fibrolamellar Carcinoma: Current Perspectives and Future Prospects.

Authors:  Georgios Polychronidis; Anastasia Murtha-Lemekhova; Juri Fuchs; Evdokia Karathanasi; Katrin Hoffmann
Journal:  Onco Targets Ther       Date:  2022-10-03       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.